Abstract:The SET nuclear proto-oncogene (SET)-nucleoporin (NUP) 214 fusion gene (SET-NUP214) is a rare leukemia fusion gene. Due to the limited number of samples with SET-NUP214 fusion gene in previous studies, the significance of SET-NUP214 for measurable residual disease (MRD) monitoring in patients with acute leukemia (AL) is still unclear. Our study aimed to observe the dynamic changes in SET-NUP214 expression before and after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and analyzed whether SET-NUP214 could be used to evaluate MRD status. Our study included 24 AL patients who were newly diagnosed with SET-NUP214 fusion gene and they all received allo-HSCT. Their MRD was evaluated by monitoring SET-NUP214 fusion gene and leukemia-associated immunophenotype (LAIP). The median follow-up time was 501 days (56-2208 days). Of the enrolled patients, 6 (25%) patients died, including 3 (12.5%) patients died of leukemia relapse. Total 5 (20.8%) patients experienced hematological relapse at a median of 225 days (56-1057 days) post-transplantation. The SET-NUP214 median expression level at diagnosis was 405.1% (14.6%-1482.4%). SET-NUP214 gene expression generally became positive prior to flow cytometry results. In addition, the Kaplan-Meier survival curves analysis showed that those who had SET-NUP214 positive (SET-NUP214+) post-transplantation had a higher 2-year cumulative incidence of leukemia relapse (CIR) of 43.7 +/- 18.8% (P < .05). However, there was no significant difference between SET-NUP214 positive and SET-NUP214 negative patients with regard to their 2-year overall survival (OS) (82.5 +/- 11.3 vs 64.6 +/- 17.5%, respectively, P = .271). ROC curve analysis turned out that the area under the ROC curve (AUC) was 0.916 (95% CI: 0.784-1.0; P = .005). In conclusion, SET-NUP214 fusion gene determined by real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) could be used to evaluate MRD status after allo-HSCT. Patients with positive SET-NUP214 expression after transplantation will have a poor prognosis.

[Expression Level of SET Gene in Acute Myeloid Leukemia and Its Clinical Significance].

New Insights into the Clinical Characteristics of SETD2-mutated Acute Myeloid Leukaemia.

Expression and Clinical Significance of ID1 Gene in Acute Myeloid Leukemia

Expression of BCL2L12 gene in de novo acute myeloid leukemia and its clinical implications]

[Clinical Significance of TET2 Gene Expression in 157 Adult Acute Myeloid Leukemia Patients with Normal Cytogenetics].

High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia from Two Cohorts.

Expression of Musashi2 gene in de novo acute myeloid leukemia and its clinical implications

[Expression Level of CDX2 Gene in Acute Myeloid Leukemia and Its Clinical Significance].

SETD2 detection may reveal response to induction therapy and survival profile in acute myeloid leukemia patients

Prognostic significance of SET-NUP214 fusion gene in acute leukemia after allogeneic hematopoietic stem cell transplantation

[Analysis of the Clinical Characteristics of 24 Cases of Hematological Malignancies with SET-NUP214 Fusion Gene].

[Clinical Analysis of SET-NUP214 Fusion Gene Positive Patients with Acute Leukemia].

Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) is Associated with Poor Prognosis in Pediatric B Lineage Acute Lymphoblastic Leukemia.

Application of SENP-1, HIF-1α and VEGF Gene Expressions in Prognostic Prediction for Normal Karyotypic Acute Leukemia Patients with NPM1 + and FLT3-ITD - .

Expression of set gene in colorectal adenocarcinoma

[Immunophenotypic and Clinical Characteristics of SET-CAN Fusion Gene Positive Acute Leukemia Patients]

Expression of CD56 in acute leukemia and its clinical significance]

A Pilot Study of Spectrum of Gene Expression of Acute Leukemia

SE translation mRNA overexpression: a potential prognostic predictor in breast cancer

Effect of Silencing SET Gene on Acute Promyelocytic Leukemia NB4-R1 Cells

Correlation between the expression level of nucleostemin gene in marrow cells of the patients with acute leukemia and its clinical types,therapy efficacy